Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

@article{Haller2011OlmesartanFT,
  title={Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.},
  author={Hermann Haller and Sadayoshi Ito and Joseph L. Izzo and Andrzej A Januszewicz and Shigehiro Katayama and Jan Menne and Albert Mimran and Ton J Rabelink and Eberhard Ritz and Luis M Ruilope and Lars Christian Rump and Giancarlo Viberti},
  journal={The New England journal of medicine},
  year={2011},
  volume={364 10},
  pages={907-17}
}
BACKGROUND Microalbuminuria is an early predictor of diabetic nephropathy and premature cardiovascular disease. We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. METHODS In a randomized, double-blind, multicenter, controlled trial, we assigned 4447 patients with type 2 diabetes to receive olmesartan (at a dose of 40 mg once daily) or placebo for a median… CONTINUE READING
Highly Influential
This paper has highly influenced 16 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS
252 Citations
28 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 252 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Similar Papers

Loading similar papers…